Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: Prospective results from the bruneck study

Circulation

Volumn 100, Issue 11, 1999, Pages 1154-1160

  Kronenberg, Florian ^a   Kronenberg, Martina F ^b   Kiechl, Stefan ^b   Trenkwalder, Evi ^b   Santer, Peter ^b   Oberhollenzer, Friedrich ^b   Egger, Georg ^b   Utermann, Gerd ^b   Willeit, Johann ^b  

^a Inst of Med Biol and Hum Genet   (Austria)

^b NONE

Author keywords

Apolipoproteins; Atherosclerosis; Carotid arteries; Genetics; Lipoproteins

Indexed keywords

APOLIPOPROTEIN A; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; ATHEROGENESIS; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; MOLECULAR WEIGHT; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; THROMBOGENESIS;

EID: 0033554451     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.11.1154     Document Type: Article

References (42)

1. Utermann G. Lipoprotein(a). In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill; 1995:1887-1912.
2. Kronenberg F, Steinmetz A. Kostner GM, Dieplinger H. Lipoprotein(a) in health and disease. Crit Rev Clin Lab Sci. 1996;33:495-543
3. Pillarisetti S, Paka L, Obunike JC, Berglund L, Goldberg IJ. Subendothelial retention of lipoprotein (a): evidence that reduced heparan sulfate promotes lipoprotein binding to subendothelial matrix. J Clin Invest 1997;100:867-874.
4. Harpel PC, Gordon BR, Parker TS. Plasmin catalyzes binding of lipoprotein(a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci U S A. 1989;86:3847-3851.
5. Loscalzo J, Weinfeld M, Fless GM, Scanu AM. Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis. 1990;10:240-245.
6. McLean JW, Tomlinson JE, Kuang W-J, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987;330:132-137.
7. Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature. 1989;339:303-305.
8. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with lipoprotein(a) Nature 1989;339: 301-303.
9. Edelberg JM, Gonzalez-Gronow M, Pizzo SV. Lipoprotein(a) inhibition of plasminogen activation by tissue-type plasminogen activator Thromb Res. 1990;57:155-162.
10. Etingin OR, Hajjar DP, Hajjar KA, Harpel PC, Nachman RL. Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells: a potential mechanism in thrombogenesis. J Biol Chem 1991;266: 2459-2465.
11. Hervio L, Chapman MJ, Thillet J, Loyau S, Anglés-Cano E. Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis. Blood. 1993;82:392-397.
12. Hervio L, Girard-Globa A, Durlach V, Anglés-Cano E. The antifibrinolytic effect of lipoprotein(a) in heterozygous subjects is modulated by the relative concentration of each of the apolipoprotein(a) isoforms and their affinity for fibrin. Eur J Clin Invest. 1996;26:411-417.
13. Leerink CB, Duif PFCCM, Verhoeven N, Hackeng CM, Leus FR, Prins J, Bouma BN, Vanrijn HJM. Apolipoprotein(a) isoform size influences binding of lipoprotein(a) to plasmin-modified des-AA-fibrinogen Fibrinolysis. 1994;8:214-220.
14. Willeit J, Kiechl S. Prevalence and risk factors of asymptomatic extracranial carotid artery atherosclerosis: a population-based study. Arterioscler Thromb. 1993;13:661-668.
15. Grouse JR, Harpold GH, Kahl FR, Toole JF, McKinney WM. Evaluation of a scoring system for extracranial carotid atherosclerosis extent with B-mode ultrasound. Stroke. 1986;17:270-275.
16. O'Leary DH, Polak JF, Wolfson SKJ, Bond MG, Bommer W, Sheth S, Psaty BM, Sharrett AR, Manolio TA, CHS Collaborative Research Group. Use of sonography to evaluate carotid atherosclerosis in the elderly: the Cardiovascular Health Study. Stroke. 1991;22:1155-1163.
17. Handa N, Matsumoto M, Maeda H, Hougaku H, Ogawa S, Fukunaga R, Yoneda S, Kimura K, Kamada T. Ultrasonic evaluation of early carotid atherosclerosis. Stroke. 1990;21:1567-1572.
18. Kiechl S, Willeit J, for the Bruneck Study Group. The natural course of atherosclerosis. Part I: incidence and progression. Arterioscler Thromb Vase Biol. 1999;19:1484-1490.
19. Kiechl S, Willeit J, for the Bruneck Study Group. The natural course of atherosclerosis. Part II: vascular remodeling. Arterioscler Thromb Vase Biol. 1999;19:1491-1498.
20. IHD Register. Report on the Fifth Working Group. Copenhagen, Denmark: World Health Organization, Regional Office for Europe: 1971.
21. Walker A, Robins M, Weinfeld F. The National Survey of Stroke: clinical findings. Stroke. 1981;12(suppl I):I-13-I-49.
22. Kamboh MI, Ferrell RE, Kottke BA. Expressed hypervariable polymorphism of apolipoprotein (a). Am J Hum Genet. 1991;49:1063-1074.
23. Kraft HG, Lingenhel A, Bader G, Kostner GM, Utermann G. The relative electrophoretic mobility of apo(a) isoforms depends on the gel system: proposal of a nomenclature for apo(a) phenotypes. Atherosclerosis 1996; 125:53-61.
24. Marcovina SM, Albers JJ, Gabel B, Koschinsky ML, Gaur VP. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem. 1995;41:246-255.
25. Willeit J, Kiechl S, Santer P, Oberhollenzer F, Egger G, Jarosch E, Mair A. Lipoprotein(a) and asymptomatic carotid artery disease: evidence of a prominent role in the evolution of advanced carotid plaques: the Bruneck Study. Stroke. 1995;26:1582-1587.
26. Kronenberg F, Kathrein H, König P, Neyer U, Sturm W, Lhotta K, Gröchenig E, Utermann G, Dieplinger H. Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease. Arterioscler Thromb. 1994;14:1405-1411.
27. Sandholzer C, Saha N, Kark JD, Rees A, Jaross W, Dieplinger H, Hoppichler F, Boerwinkle E, Utermann G. Apo(a) isoforms predict risk for coronary heart disease: a study in six populations. Arterioscler Thromb. 1992;12:1214-1226.
28. Wild SH, Fortmann SP, Marcovina SM. A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants. Arterioscler Thromb Vasc Biol. 1997;17:239-245.
29. Klausen IC, Sjol A, Hansen PS, Gerdes LU, Moller L, Lemming L, Schroll M, Faergeman O. Apolipoprotein(a) isoforms and coronary heart disease in men: a nested case-control study. Atherosclerosis. 1997;132:77-84.
30. Badimon JJ, Fuster V, Chesebro JH, Badimon L. Coronary atherosclerosis: a multifactorial disease. Circulation. 1993;87(suppl II):II-3-II-16.
31. Brown SA, Morrisett JD, Boerwinkle E, Hutchinson R, Patsch W. The relation of lipoprotein(a) concentrations and apolipoprotein(a) phenotypes with asymptomatic atherosclerosis in subjects of the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb. 1993;13: 1558-1566.
32. Armstrong VW, Cremer P, Eberle E, Manke A, Schulze F, Wieland H, Kreuzer H, Seidel D. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis: dependence on serum LDL levels. Atherosclerosis. 1986;62:249-257.
33. Maher VMG, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA. 1995;274:1771-1774.
34. Hopkins PN, Wu LL, Hunt SC, James BC, Vincent GM, Williams RR. Lipoprotein(a) interactions with lipid and nonlipid risk factors in early familial coronary artery disease. Arterioscler Thromb Vasc Biol. 1997; 17:2783-2792.
35. Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science. 1993;260:1655-1658.
36. Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC. Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice. Nature. 1994;370:460-462.
37. Grainger DJ, Kemp PR, Metcalfe JC, Liu AC, Lawn RM, Williams NR, Grace AA, Schofield PM, Chauhan A. The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis. Nat Med. 1995;1:74-79.
38. Syrovets T, Thillet J, Chapman MJ, Simmet T. Lipoprotein(a) is a potent chemoattractant for human peripheral monocytes. Blood. 1997;90: 2027-2036.
39. Poon M, Zhang XX, Dunsky KG, Taubman MB, Harpel PC. Apolipoprotein(a) induces monocyte chemotactic activity in human vascular endothelial cells. Circulation. 1997;96:2514-2519.
40. Takami S, Yamashita S, Kihara S, Ishigami M, Takemura K, Kume N, Kita T, Matsuzawa Y. Lipoprotein(a) enhances the expression of intercellular adhesion molecule-1 in cultured human umbilical vein endothelial cells. Circulation. 1998;97:721-728.
41. Gazzaruso C, Geroldi D, Garzaniti A, Falcone C, Fratino P, Finardi G, Buscaglia P. Apolipoprotein(a) phenotypes as genetic markers of coronary atherosclerosis severity. Int J Cardiol. 1998;64:277-284.
42. Kronenberg F, Neyer U, Lhotta K, Trenkwalder E, Auinger M, Pribasnig A, Meisl T, König P, Dieplinger H. The low molecular weight apo(a) phenotype is an independent risk factor for coronary artery disease in hemodialysis patients: a prospective follow-up. J Am Soc Nephrol. 1999; 10:1027-1036.